Retro Biosciences

Reprogramming, autophagy, plasma factors · Whole-organism aging

PreclinicalPartial Epigenetic Reprogramming

Mechanism

Reprogramming, autophagy, plasma factors

Intervention class

Cell / small molecule

Indication

Whole-organism aging

Stage

Preclinical

Evidence

animal

Funding

$1.0B (Sam Altman)

Backers

Sam Altman

Overview

Mission: add 10 years to healthy human lifespan. Three pillars — cellular reprogramming, autophagy, and plasma-inspired therapeutics. Largely preclinical.

Technology

Retro Biosciences works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.

Read the Partial Epigenetic Reprogramming brief →

Related companies

Altos Labs

Partial epigenetic reprogramming

Life Biosciences

Partial reprogramming (OSK via AAV)

NewLimit

Epigenetic reprogramming (factor discovery)

Rejuvenate Bio

Gene therapy (FGF21, sTGFβR2, klotho); reprogramming

Turn Biotechnologies

mRNA epigenetic reprogramming

Shift Bioscience

Reprogramming w/o dedifferentiation

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.